Platinum‐containing chemotherapy probably leads to higher participants requiring dose reduction compared with chemotherapy without platinum (moderate certainty).
Platinum‐containing chemotherapy probably leads to higher anaemia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
Platinum‐containing chemotherapy showed no clear difference in febrile neutropenia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
The review found no eligible studies for this question.
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to higher pathological complete response compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
ATRA in addition to chemotherapy showed no clear difference in mortality (instead of overall survival) compared with chemotherapy only (moderate certainty).
The review found no eligible studies for this question.
ATRA in addition to chemotherapy showed no clear difference in mortality, relapse and progresses (instead of disease‐ or… compared with chemotherapy only (moderate certainty).
ATRA in addition to chemotherapy showed no clear difference in on‐study mortality compared with chemotherapy only (moderate certainty).
ATRA in addition to chemotherapy showed no clear difference in infection grade III/IV compared with chemotherapy only (moderate certainty).
It is very uncertain whether ATRA in addition to chemotherapy changes diarrhoea grade III/IV compared with chemotherapy only (very low certainty).
It is very uncertain whether ATRA in addition to chemotherapy changes nausea/vomiting grade III/IV compared with chemotherapy only (very low certainty).
It is very uncertain whether ATRA in addition to chemotherapy changes cardiac toxicity grade III/IV compared with chemotherapy only (very low certainty).
Chemotherapy plus lower‐dose radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus higher‐dose radiation (low certainty).